For postmenopausal women with overweight or obesity receiving tirzepatide, menopausal hormone therapy linked to increased weight loss.

Key Takeaways ・The weight-loss drug tirzepatide reduced both body fat and tumor growth in obese mice with breast cancer. ・Tumor size closely matched body weight and fat levels, suggesting fat ...

Postmenopausal women struggling with weight loss may find a powerful solution by combining the diabetes drug tirzepatide with ...

Another pivotal study, published in 2022 in the New England Journal of Medicine, found that tirzepatide helped people with overweight or obesity lose an average of 21 percent of their body weight ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type ...

In patients with obesity, tirzepatide improved cardiometabolic parameters and risk for cardiovascular disease, but the ...

Tirzepatide and semaglutide are type 2 diabetes drugs often used for weight loss. While tirzepatide may potentially be more effective, it's too early to know that based on current research.

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Over the course of 72 weeks, people on tirzepatide lost an average of 20.2% of their body weight, or about 50 pounds. Those on semaglutide lost 13.7%, around 33 pounds.

A new study explores the reasons why tirzepatide, the once-weekly injection used to treat obesity and type 2 diabetes, is associated with greater weight loss in women than men.

When prescribing glucagon-like peptide 1 (GLP-1) medications, many physicians prefer tirzepatide over the more well-known semaglutide due to its superior efficacy in weight loss and A1c reduction ...

At 176 weeks, the mean percent change in body weight among the participants who received tirzepatide was −12.3% with the 5-mg dose, −18.7% with the 10-mg dose, and −19.7% with the 15-mg dose ...